Multiple Sclerosis

Multiple sclerosis is a common condition of young people and mature adults, affecting nearly a million Americans. The most common form is Relapsing-Remitting, but there are also Primary Progressive, Secondary Progressive, and Progressive-Relapsing subtypes. New trials are directed against the disease itself, hoping to slow progression, or against particular symptoms like spasticity (stiffness of muscles and limbs).

Condition(s) Type of Drug Phase Add-On Placebo Duration Open Label Extension
Relapsing-Remitting Multiple Sclerosis B-cell depleting once-monthly subcutaneous injection vs. Aubagio III Yes 50% 12 months Yes
Relapsing-Remitting Multiple Sclerosis Novel oral agent vs. Tecfidera III Yes 50% 12 months Yes

Response Form

If you or a loved one is interested in participating in one of our trials, please contact us at (855) 829-8899 or use the form below. One of our skilled Clinical Research Coordinators will contact you as soon as possible. Thank you for your interest in our research!

- Stephen S. Flitman, MD, Medical Director

Your Name
Name of Patient
Email Address
Your Telephone
Best Time to Call
Comments
 Ready?